August 15, 2024 – Pfizer Inc. introduced optimistic topline security and immunogenicity outcomes from substudy B of the continued pivotal Part 3 medical trial (NCT05842967) MONET cash (HSV I Mammunition ONResearch for adults Ts at increased danger of extreme illness), evaluating two doses of the ABRYSVO vaccine in immunocompromised adults 18 years of age and older who’re […]